Texas meeting 30th March to 2nd April 2011
The fourth biennial Insight meeting, held from 30th March to 2nd April 2011 in Texas was a great success. The meeting was very well organized by our hosts Drs. Patrich Lynch and Dr.Michael Rodriguez Bigas.
As you can see on the map participants came from all over the world. A group picture can be downloaded here.
Below you will find the conference agenda. Several of the presentations are available for viewing by clicking on the presenting author.
Thursday, March 31, 2011
Plenary Session I: Lynch Syndrome
Jeremy Jass Lecture - Introduction by Susan Parry, MD
Current Status of Serrated Polyps: Clinicopathologic and Molecular Considerations
Stanley R. Hamilton, MD
Basic Science Abstracts
Chairpersons: Rolf H. Sijmons, MD, PhD; and Marc Greenblatt, MD
Functional analysis of a germline promotor variant to determine its role in epigenetic silencing of MLH1 in a Lynch syndrome family
Robert W. Rapkins, PhD
Constitutional MLH1 epimutations can occur in association with promotor variants
Megan P. Hitchins, PhD
MLH1 constitutional epimutation in a patient with early-onset Lynch syndrome
Gabriel Capella, MD, PhD
Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early onset familial colorectal cancer
Roland Kuiper, PhD
Promotor methylation of DKK1 and SFRP1 associate with opposing tumor subtypes in a large cohort of colorectal cancers
Bharati Bapat, PhD
Combined DNA- and RNA-based mutation detection in PMS2 identifies two cases with mono-allelic expression
Heleen M. van der Klift, MSc
Determining the impact of GALNT12 germline mutations in hereditary colorectal cancer
Michael Woods, PhD
Plenary Session II: Basic Science
Chairpersons: Thomas K. Weber, MD; and Megan P. Hitchins, PhD
Serum antibodies against tumor-specific frameshift peptides in Lynch syndrome as a potential tumor-related marker
Miriam Reuschenbach, MD, PhD
Beta2-microglobulin mutations and NK cell mediated cytotoxity in microsatellite unstable colorectal cancer
Matthias Kloor, MD
Defects of HLA class antigen expression and infiltration with CD4-positive T cells in MSI-H colorectal cancer
Anita Voigt, MSc
Comprehensive database of patients from the German HNPCC Consortium with MLH1 missense variants and functional studies
Brigitte Royer-Pokora, PhD
International approach to classifying DNA mismatch repair gene missense mutations in The Netherlands
Rolf H. Sijmons, MD, PhD
A simplified method for segregation analysis (SISA) to determine penetrance and expression of a genetic variant in a family
Pål Møller, MD, PhD
Dependence of colorectal cancer risk on the parent of origin of mutations in DNA mismatch repair genes
John Hopper, PhD
Both parents affected with bowel cancer affords risk equivalent to early onset colorectal cancer
Finlay Macrae, MD
Warthin Lecture - Introduction by Patrick M. Lynch, MD, JD
Historical Aspects of the Lynch Syndrome, ICG-HNPCC, and InSiGHT
Hans Vasen, MD, PhD
Plenary Session III: Cancer Risk
Chairpersons: Marsha Frazier, PhD; and Inge Bernstein, MD, PhD
High colorectal and low endometrial cancer risk in EPCAM deletion positive Lynch syndrome
Marjolijn J. Ligtenberg, PhD
Cancer risk in Lynch syndrome families diagnosed with a PMS2 mutation
Juul T. Wijnen, PhD
Investigating the risk of bladder cancer among HNPCC-patients with confirmed MMR-gene mutations
Bharati Bapat, PhD
Smoking and alcohol consumption and colorectal adenoma risk in Lynch syndrome: The GEOLynch cohort study & Dietary patterns and colorectal adenomas in Lynch syndrome: The GEOLynch cohort study
Akke Botma, MSc
Knowledge of gynecologic cancer risk and screening in women from HNPCC families
Zohreh Ketabi
Meera Khan Lecture - Introduction by Miguel A. Rodriguez-Bigas, MD
"Clinical Benefit" in FAP: Who Decides?
Ernest Hawk, MD, MPH
Plenary Session IV: Identification, Surveillance, and Treatment
Chairpersons: Benedito Rossi, MD, PhD; and Susan Clark, MD
Comprehensive comparison of five different models to predict MMR-mutation carriers
Silke Zachariae, PhD
Performance of PREMM1,2,6 MMRPREDICT and MMRPRO in detecting Lynch syndrome among endometrial cancer cases
Rowena C. Mercado, MD, MPH
Screening for Muir-Torre syndrome using mismatch repair gene immunohistochemistry of sebaceous skin lesions
Maegan E. Roberts, MS
Metachronous colorectal cancer risk for mismatch repair mutation carriers: the advantage of more extensive surgery
Susan Parry, MD
Extended colonic resection does not impair quality of life in individuals with familial bowel cancer or polyps
Claudia Schneider
Post-surgical surveillance in Lynch syndrome - A Cleveland Clinic experience
Susan Fay, AA
Clinical significance of FDG-PET examinations for surveillance in patients with Lynch syndrome
Masami Arai, MD
Microsatellite instability and chemotherapy response in the prospective German FOGT-4 trial
Anna Tikidzhieva
Friday, April 1, 2011
Plenary Session V: Epidemiology, Clinical FAP and MAP
Chairpersons: Susan Peterson, PhD, MPH; and Sapna Syngal, MD, MPH
Differences in phenotypic characteristics between APC and biallelic MUTYH mutation carriers among 1193 individuals with attenuated polyposis
Shilpa Grover, MD, MPH
Cancer risk for monoallelic MUTYH mutation carriers with a family history of colorectal cancer
Aung Ko Win, MBBS, MPH ; and Mark A. Jenkins, PhD
Evidence for accelerated colorectal-adenoma progression in MAP
Marry H. Nieuwenhuis, MSc, MD
Origin of colorectal cancers in high-risk serrated neoplasia patients
Joanne Young, PhD
Serrated polyposis syndrome and colonoscopic surveillance: who is it safe to follow
Susan Parry, MD
Disclosing genetic research results: experience of the colon cancer family registry
Louise Keogh, PhD
Comparison of screening outcomes in patients with a family and personal history of colorectal neoplasia
Finlay Macrae, MD
Bussey Lecture -Introduction by John Baron, MD
Chemoprevention with Natural Products - Current Status
Finlay Macrae, MD
Plenary Session VI: Chemoprevention and Colorectal Surgery
Chairpersons: Judy Ho, MBBS; and Francisco Lopez-Kostner, MD
Repression of polyp formation and growth by highly pure eicosapentaenoic acid in APCMIN/+ mice
Luigi Ricciardiello, MD
Eicosapentaenoic acid free fatty acid reduces the number of rectal polyps in FAP
Nicholas J. West, FRCS
Abdominal symptoms in relation to perceived health in patients with FAP
Kaisa Fritzell, RN, MSc
Prophylactic surgery for FAP - using the ‘rectal retention index' to guide surgical choice
Ashish Sinha, MD, MSc
Female fertility after colorectal surgery for FAP. A nationwide cross-sectional study
Marry H. Nieuwenhuis, MSc, MD
Is proctectomy after Ileorectal anastomosis in FAP always possible? What about reconstruction?
James Church, MD
Rectal survival outcomes in screen detected adolescents 18 yrs or younger with FAP
Sreelakshmi Mallappa, MRCS
Technical problems with ileal pouches in patients with FAP: what happens when pouches go bad
James Church, MD
Eldon Gardner Lecture - Introduction by Randall Burt, MD
Genome Wide Association Studies (GWAS) and Cancer Risk
Prof. Ian Tomlinson, MD, PhD
Plenary Session VII: Duodenal Polyposis and Desmoid Disease
Chairpersons: Allan Spigelman, MD; and Andrew Latchford, MD
Outcome of 20 years of duodenal surveillance in FAP: the DAF II study
Steffen Bülow, MD, DMSc
Advanced duodenal disease in FAP: how frequently should patients be followed up
Susan Clark, MD
Surgical management for advanced duodenal adenomatosis and cancer in Dutch patients with FAP
Bjorn W.H. van Heumen, MD
A positive family history, abdominal surgery, and a 3' APC mutation are evident risk factors for desmoid tumors in FAP: An International cohort study
Lucio Bertario, MD, PhD
Risk factors predicting intra-abdominal desmoid development in FAP
Ashish Sinha, MD, MRCS
FAP related desmoids presenting with air-fluid - A clinical review and management algorithm
Pravin Ranchod, FRACS
Long-term outcome of FAP-associated and sporadic desmoid tumours in 154 patients
Daniel R. Quast
A nation-wide study comparing sporadic and familial adenomatous polyposis (FAP) related desmoid-type fibromatosis
Marry H. Nieuwenhuis, MSc, MD
Postoperative prophylactic administration of antiestrogens and sulindac inhibits desmoid growth in FAP patients after prophylactic colectomy
Emanuel Burdzik
Ian Todd Lecture -Introduction by Prof. Robin Phillips
Early Onset and Familial Colorectal Cancer That is Not Lynch Syndrome
C. Richard Boland, MD
David Jagelman Case Presentations Corner
James Church, MD
Saturday, April 2, 2011
Plenary Session VIII: Peutz-Jeghers Syndrome, Juvenile Polyposis, Cowden Syndrome, Hereditary Pancreatic and Gastric Cancer
Chairpersons: Prof. Robin Phillips; and Finlay Macrae, MD
High cumulative and relative cancer risk and increased mortality in patients with Peutz-Jeghers syndrome
Monique van Leerdam, MD, PhD, MSc
Peutz-Jeghers syndrome and family planning: the attitude towards prenatal genetic testing
Susanne E. Korsse, MD
Expanding our understanding of the gastrointestinal phenotype in PTEN-hamartoma tumor syndrome
Brandie Heald Leach, MS
Is colorectal surveillance indicated in patients with the PTEN hamartoma tumor syndrome?
C. Marleen Kets, MD, PhD
Juvenile polyposis syndrome - a study of genotype, phenotype and long-term outcome
Andrew Latchford, MD
The prevalence of hereditary hemorrhagic telangiectasia in a cohort of patients with juvenile polyposis syndrome
Margaret O'Malley, BS
Indication for CDKN2A mutation analysis in familial pancreatic cancer-families without occurrence of melanomas
Femme Harinck, MD
Lessons from the Family Health Promotion Project
Dennis J. Ahnen, MD
Plenary Session IX: Late Breaking News and Clinical Trials
Chairpersons: Miguel A. Rodriguez-Bigas, MD; and Patrick M. Lynch, MD, JD
Update on CAPP2
Sir John Burn, MD